- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02160366
Profile Related Evidence to Determine Individualized Cancer Therapy (PREDICT) Program in Advanced Cancer Patients
Aperçu de l'étude
Description détaillée
Molecular Profiling/Deep Sequencing:
Molecular profiling is the classification of tissue based on the expression of certain genes within a tumor that might predict how the tumor responds to therapy. Deep sequencing is a more detailed type of molecular profile that allows for a more focused analysis of individual genes.
Biomarker Data:
A characteristic that is measured and evaluated as an indicator of normal biologic processes, disease processes or pharmacologic responses to a therapeutic intervention.
Study Participation:
If you agree to take part in this study, information from your medical record will be collected. The information that researchers will collect includes your medical history, chemotherapy schedule(s), as well as the results of any tests, procedures, and/or therapies you may have had. Your responses to the therapies, your side effects, and the results of any diagnostic tests performed during therapy will also be collected.
Researchers want to learn if they could have better predicted your response to therapy using the information collected in this study and/or better predict side effects from your treatment.
The data collected from your medical record will be stored in a password-protected database at MD Anderson to be used in research related to this study for up to 10 years.
In addition, research studies on new biomarkers may be conducted on your previously banked blood and/or tumor tissue. Samples collected may include blood, fresh tumor tissue, urine, saliva, bone marrow, pleural fluid, ascites, skin or hair follicle.
Your name, medical record number, and any other personal identifiable information collected from your medical record will be replaced with a code number. No identifying information will be directly linked to the data collected from your medical record. Only the doctor who is in charge of this study, and select members of their research staff, will have access to the code numbers and be able to link any of the data back to you.
Use of Samples:
Before your banked tissue samples can be used for research, the people doing the research must get specific approval from the Institutional Review Board (IRB) of MD Anderson. The IRB is a committee made up of doctors, researchers, and members of the community. The IRB is responsible for protecting the participants involved in research studies and making sure all research is done in a safe and ethical manner. All research done at MD Anderson, including research involving your tissue samples from this bank, must first be approved by the IRB.
Your tissue samples will be given a code number. No identifying information will be directly linked to your samples. Only the researcher in charge of the bank will have access to the code numbers and be able to link the samples to you. This is to allow medical data related to the samples to be updated as needed. Other researchers using your samples will not be able to link this data to you.
Length of Study:
Your participation in this study will be over after either the data, blood, tumor tissue samples, and/or archived tumor samples are analyzed.
This is an investigational study.
Up to 2000 participants will take part in this study. All will be enrolled at MD Anderson.
Type d'étude
Inscription (Anticipé)
Contacts et emplacements
Lieux d'étude
-
-
Texas
-
Houston, Texas, États-Unis, 77030
- Recrutement
- University of Texas MD Anderson Cancer Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
1. All patients referred to the Clinical Center for Targeted Therapy are potentially eligible for recruitment.
Exclusion Criteria:
n/a
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Biomarker/Molecular Data Collection and Analyzation
Advanced cancer participants
|
Research studies on new biomarkers conducted on previously banked blood and/or tumor tissue.
Samples collected may include blood, fresh tumor tissue, urine, saliva, bone marrow, pleural fluid, ascites, skin or hair follicle.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Comparison of Biomarker Profiling to Treatment Outcome
Délai: 2 months
|
For correlating marker profiles with response to treatment, univariate and multivariate (multiple covariates) logistic regression used, with response status taken as outcome variable.
Distributions of time-to-event outcomes estimated using Kaplan-Meier curves, and these distributions compared among groups using log rank test.
|
2 months
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Filip Janku, MD, PHD, M.D. Anderson Cancer Center
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- LAB10-0441
- 3UL1RR024148-04S1 (Subvention/contrat des NIH des États-Unis)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Cancers avancés
-
Qilu Pharmaceutical Co., Ltd.Pas encore de recrutementCLDN18.2 Positif Advanced Biliary Tracts Cancer
-
Azienda Ospedaliera Universitaria Integrata VeronaComplétéScaphoïde non-Union Advanced Effoncé (poignet SNAC)
-
Hoffmann-La RocheRésiliéAdvanced BRAFV600 Mélanome de type sauvageÉtats-Unis, Corée, République de, Australie, Belgique, France, Fédération Russe, Italie, Pays-Bas, Espagne, Royaume-Uni, Brésil, Pologne, Allemagne, Grèce, Hongrie
-
Advanced BionicsComplétéPerte auditive sévère à profonde | chez les utilisateurs adultes du système d'oreille bionique Advanced Bionics HiResolution™États-Unis
-
National University Hospital, SingaporeEDDC (Experimental Drug Development Centre), A*STAR Research EntitiesRecrutementAvec MSS/pMMR Advanced, cancer de l'ovaire résistant au platineSingapour
Essais cliniques sur Biomarker Research
-
Arizona Oncology ServicesInconnueCancer du sein localisé | Cancer localisé de la prostate | Patients recevant une radiothérapie externeÉtats-Unis
-
Oregon Health and Science UniversityComplétéSyndrome du canal carpienÉtats-Unis
-
University of CalgaryRecrutementIntolérance orthostatique | Syndrome de tachycardie posturaleCanada
-
Bryan TompsonComplétéLe taux ou le mouvement dentaire orthodontiqueCanada
-
Erasmus Medical CenterInscription sur invitation
-
CochlearComplété
-
Pennington Biomedical Research CenterActif, ne recrute pasPerte de poids | Vieillissement | Adhésion au traitementÉtats-Unis
-
Mayo ClinicNational Cancer Institute (NCI)Pas encore de recrutement
-
EchosensComplétéObésité morbide | Fibrose du foieFrance